Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.

Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology an...

ver descrição completa

Detalhes bibliográficos
Autores: Olivares Berjaga, David, Martínez Pinteño, Albert, Rodríguez Ferret, Natalia, Mas Herrero, Sergi, Morén Núñez, Constanza, Parellada Rodón, Eduard, Gassó Astorga, Patricia
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/227722
Acesso em linha:https://hdl.handle.net/2445/227722
Access Level:acceso abierto
Palavra-chave:Esquizofrènia
Farmacologia
Antipsicòtics
Schizophrenia
Pharmacology
Antipsychotic drugs
id ES_76d9a7cb6e9bf6bcaa43ee8d1055d015
oai_identifier_str oai:recercat.cat:2445/227722
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.Olivares Berjaga, DavidMartínez Pinteño, AlbertRodríguez Ferret, NataliaMas Herrero, SergiMorén Núñez, ConstanzaParellada Rodón, EduardGassó Astorga, PatriciaEsquizofrèniaFarmacologiaAntipsicòticsSchizophreniaPharmacologyAntipsychotic drugsSchizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.Nature Publishing Group2026202620252026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion14 p.application/pdfhttps://hdl.handle.net/2445/227722Articles publicats en revistes (Medicina)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1038/s41398-024-03194-2Translational Psychiatry, 2025, vol. 15, num.1https://doi.org/10.1038/s41398-024-03194-2cc-by (c) Olivares-Berjaga, D. et al., 2025http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2277222026-05-29T05:05:01Z
dc.title.none.fl_str_mv Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
title Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
spellingShingle Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
Olivares Berjaga, David
Esquizofrènia
Farmacologia
Antipsicòtics
Schizophrenia
Pharmacology
Antipsychotic drugs
title_short Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
title_full Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
title_fullStr Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
title_full_unstemmed Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
title_sort Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
dc.creator.none.fl_str_mv Olivares Berjaga, David
Martínez Pinteño, Albert
Rodríguez Ferret, Natalia
Mas Herrero, Sergi
Morén Núñez, Constanza
Parellada Rodón, Eduard
Gassó Astorga, Patricia
author Olivares Berjaga, David
author_facet Olivares Berjaga, David
Martínez Pinteño, Albert
Rodríguez Ferret, Natalia
Mas Herrero, Sergi
Morén Núñez, Constanza
Parellada Rodón, Eduard
Gassó Astorga, Patricia
author_role author
author2 Martínez Pinteño, Albert
Rodríguez Ferret, Natalia
Mas Herrero, Sergi
Morén Núñez, Constanza
Parellada Rodón, Eduard
Gassó Astorga, Patricia
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Esquizofrènia
Farmacologia
Antipsicòtics
Schizophrenia
Pharmacology
Antipsychotic drugs
topic Esquizofrènia
Farmacologia
Antipsicòtics
Schizophrenia
Pharmacology
Antipsychotic drugs
description Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/227722
url https://hdl.handle.net/2445/227722
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41398-024-03194-2
Translational Psychiatry, 2025, vol. 15, num.1
https://doi.org/10.1038/s41398-024-03194-2
dc.rights.none.fl_str_mv cc-by (c) Olivares-Berjaga, D. et al., 2025
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Olivares-Berjaga, D. et al., 2025
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 14 p.
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411080254521344
score 15,811543

Registos relacionados